Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

In a turbulent market environment, Moderna Inc (BMV:MRNA). shares have touched a 52-week low, sinking to $30.7, with concerning financial metrics showing negative EBITDA of $2.36 billion and gross ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

MRNA is also committed to becoming a more efficient organization, given that it reduced its operating costs by more than 25% in 2024, compared to 2023. Investors are bullish on the stock because ...

which MRNA is developing in partnership with Merck (MRK), to lift MRNA stock this year. Ellison’s Statement on Potential Cancer Vaccines Last week, Oracle Chairman Larry Ellison asserted that AI ...